Biorestorative Therapies, Inc. · NASDAQ:BRTX
Biorestorative Therapies — Investor Presentation (December 2013)
26 slides from Biorestorative Therapies's investor presentation, Dec 4, 2013
Slide 1: BioRestorative Therapies: A Stem Cell Biotechnology Company
biorestoratlve BioRestorative Therapies: A Stem Cell Biotechnology Company biorestordtlve December 2013 ¢ OTC/BB: BRTX °¢ biorestorative.com a
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the “Company”) to develop its adult stem cell business, the future of regenerative medi
Slide 3: Corporate Overview
man Corporate Overview Second-Generation Stem Cell Regenerative Medicine Company BioRestorative Therapies (“BRT”) is a life sciences company focused on adult stem cell-based cellular therapies for various personal medical applications. BRT develops products and medical procedures using cell and tiss
Slide 4: Investment Highlights
ga /nvestment Highlights Spinal disc program is poised to enter Clinical Trials — IRBapproval secured — Retrospective human safety/feasibility study underway Proprietary therapeutic disc delivery device offers additional opportunities for value creation Further pipeline products address large market
Slide 5: Lead Therapeutic Program
gun Lead Therapeutic Program biorestordtlve
Slide 6: brtxDISC Overview
mae OrtxDISC™ Overview brtxDISC™ (Disc Implanted Stem Cells) Program Non-surgical stem cell treatment for bulging and herniated disc disease Outpatient procedure performed in a physician’s office is intended for patients who have failed all non-surgical disc treatments and face surgery Addresses unm
Slide 7: brtxDISC Target Markets
brtxDISC™ Target Markets Discectomy- . brt, Bulge/HNP SC biorestordtlve
Slide 8: brtxDISC Market Size & Costs
uum DItxDISC™ Market Size & Costs Annual brtxDISC™ Procedure Incidence Surgical Cost (Estimated Somneerer (U.S.) Cost) Spinal Fusion 300,000 $75-100K $18K $57-82K lee 200,000 $35-50K $18K $17-32K Replacement “p Discectomy 200,000 $20-50K $18K $2-32K Surgical procedures are typically followed by an a
Slide 9: IP -- Advantages
mum /P -- Advantages | 1. Proprietary Cell Culturing | | 2. Proprietary Therapeutic Delivery Device
Slide 10: brtxDISC Cell Culturing
wae DrtxDISC™ Cell Culturing ¢ Utilizes patient’s own stem cells to repair damaged tissue ¢ Disc procedure requires the selection of mesenchymal stem cells that can survive in low oxygen (hypoxic) and avascular (lack of blood supply) environment e IP Filed 12/4/2009: Methods and Compositions to Faci
Slide 11: brtxDISC Cell Delivery Device
mun OFtxDISC™ Cell Delivery Device « Essential to the success of the treatment « Enables physician to deliver cells at precise location within damaged disc IP Filed 11/4/2010: Therapeutic Delivery Device IP Status: Discussions with patent office biorestoratlve o erapies
Slide 12: Delivery Device Animation
mum Delivery Device Animation dise® 12 therapies
Slide 13: Short Physician Learning Curve
gan Short Physician Learning Curve Certain physicians already trained and skilled in performing disc injections 5 Groups Physiatrists Pain Management Physicians Interventional Radiologists Orthopedic Spine Physicians Neurosurgeons bi orestorave 1800 therapies
Slide 14: brtxDISC Process Overview
mum DItxDISC™ Process Overview Physician purchases collection/delivery device kit ia Patient receives cells via brtxDISC™ Delivery Device in physician’s office Physician collects patientcell sample BRT sends therapeutic cells/dose back to physician cells for lab culturing to BRT | Physician sends pa
Slide 15: brtxDISC MRI Results
brtxDISC™ MRI Results * 42y/o Male: Annulartear at L5-S1 noted on 2003 MRI and radiculopathy diagnosed. 2007 MRI showed a mild L5-S1 disc bulge. ¢ Treated in Physician’s Office: 5-month follow-up MRI showed complete resolution of the L5-S1 disc bulge on both sagittal and axial slices with some concu
Slide 16: brtxDISC Near-Term Goals
mae OrtxDISC™ Near-Term Goals 16 Finalize retrospective safety study of treated patients; submit results for publication (1Q 2014) Complete FDA-related work pertaining to the therapeutic delivery device (1Q 2014) Hold pre-trial meeting with FDA (2Q 2014) Finalize trial preparation and file IND/IDE w
Slide 17: Pipeline Programs
mun Pipeline Programs ThermoStem® Program (Brown Fat Stem Cells) Potential Treatments for Type 2 Diabetes and Obesity brtx-C Cosmetic Program Primary ingredient potential for incorporation into new generation ofanti-aging beauty products biorestoratlve o erapies
Slide 18: ThermoStem — Brown Fat Program
ThermoStem — Brown Fat Program “One of the most powerful organs in the body....Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia. ” - Aaron M. Cypress, M.D., Ph.D., Joslin Diabetes
Slide 19: Brown Fat Cells Implanted in a Biological Scaffold
| Brown Fat Cells Implanted in a Biological Scaffold Cell delivery method incorporates subcutaneous implant of decellularized scaffold containing brown fat 19 biorestordtlve
Slide 20: Brown Adipose Regulates Glucose
mun Brown Adipose Regulates Glucose Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant ‘Subhadra C. Gunawardana and David W. Piston Brown adipose tissue regulates glucose homeostasis and insulin sensitivity Kristin | Stanford, Rooland J.W. Middolbook, Kristy L_ Townsend, Ding An,
Slide 21: Preclinical — Glucose/Weight
mu Preclinical — Glucose/Weight Basal Blood Glucose Levels Body Weight 600 40 soo A B 30 400 * 3 § : £ = = 300 Ser $20 3 a. 200 10 100 5 ° ° 2203 4 5 6 7 8 9 1041 12 13 —eHcontral 10203 4 5 6 7 8 8 40 4112 13 ~eXcontral ‘Weeks after transplantation — Weeks after transplant ey Fig. 7. (A) Glucose lev
Slide 22: Preclinical — Trig/Chol Levels
mamas Preclinical — Trig/Chol Levels ™ Baseline @1Mth © 2Mth @3Mth = 4Mth Trig-ctrl mg/dL Trig—tx mg/dL Chol-ctrl mg/dL Chol-tx mg/dL Baseline 1Mth 2Mth 3Mth 4Mth Trig—ctrl mg/dt 115416 147413 159421 165414 18816 Trig — tx mg/d 120414 142415 13119 113411 114410 Chol— ctrl mg/dt 136416 1515615 188426
Slide 23: Publication in STEM CELLS
Publication in STEM CELLS STEM CELLS® MANUSCRIPT SECTION: TISSUE-SPECIFIC STEM CELLS Metabolically Active Human Brown Adipose Tissue Derived Stem Cells Francisco J Silva*!, Dolly J Holt*!, Vanessa Vargas!, James Yockman!, Sihem Boudina”, Donald % Atkinson!, David W Grainger’, Monica P Revelo’, Warre
Slide 24: brtx-C Cosmetic Overview
brtx-C Cosmetic Overview Human Cellular Extract * BRThas developed an adult stem cell-derived extract for incorporation into beauty products manufactured by third parties — Potential use as a primary ingredient for a new generation of “anti-aging” beauty products (lyophilized supernatantim — BRT see
Slide 25: Spinal disc program is poised to enter Clinical Trials
Spinal disc program is poised to enter Clinical Trials — IRBapproval secured — Retrospective human safety/feasibility study underway Proprietary therapeutic disc delivery device offers additional opportunities for value creation Further pipeline products address large markets — Developing cellular t
Slide 26: ldm1.jpg ldm2.jpg ldm3.jpg ldm4.jpg ldm5.jpg ldm6.jpg ldm7.jpg ldm8.jpg ldm9.jpg ldm10.jpg ldm11.jpg ldm12.jpg ldm13.…
ldm1.jpg ldm2.jpg ldm3.jpg ldm4.jpg ldm5.jpg ldm6.jpg ldm7.jpg ldm8.jpg ldm9.jpg ldm10.jpg ldm11.jpg ldm12.jpg ldm13.jpg ldm14.jpg ldm15.jpg ldm16.jpg ldm17.jpg ldm18.jpg ldm19.jpg ldm20.jpg ldm21.jpg ldm22.jpg ldm23.jpg
BioRestorative Therapies — Investor Presentation (December 2013) on 6ix